Company Overview
Snapshot
Founded in October 2022 by Dikla Berko-Ashur, Sakura Bio operates with 1–10 employees. The company has raised $1.7M across one funding round from one investor. In May 2025, Sakura Bio secured Pre-Seed funding from VLX Ventures.
Business overview
Sakura Bio is a Health Tech & Life Sciences company focused on developing off-the-shelf allogeneic T-cell therapies to combat cancer, particularly acute myeloid leukemia. Its core technology centers on creating super-activated killer cells, an allogeneic T-cell therapy derived from naïve PBMCs through a relatively short manipulation process. The company's lead product, Super Activated Killer T-cell (SAK-T), is designed to offer superior anti-tumor cytotoxic activity without toxicity to healthy tissue, distinguishing it from other T-cell-based products like CAR-T by providing a high safety profile and no graft-versus-host disease. Sakura Bio operates in the Pharmaceuticals, Drugs Discovery & Development sectors, targeting healthcare and laboratory markets with a B2B2C and B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What is Sakura Bio's primary focus?
- Sakura Bio is developing an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy designed to fight cancer, with a particular focus on acute myeloid leukemia.
- What is the company's lead product?
- Sakura Bio's lead product is Super Activated Killer T-cell (SAK-T), a unique T-cell population engineered for superior anti-tumor cytotoxic activity without toxicity to healthy tissue.
- When was Sakura Bio founded?
- Sakura Bio was founded in October 2022.
- What is the safety profile of SAK-T cells?
- SAK-T cells are designed to have a high safety profile, with no graft-versus-host disease, allowing them to be developed as an off-the-shelf T-cell product.
- Which investor participated in Sakura Bio's Pre-Seed funding round?
- In May 2025, Sakura Bio secured Pre-Seed funding from.